CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

NCT03370159 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor decided not to move forward

Conditions

Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

DRUG: 6,8-Bis(benzylthio)octanoic Acid
DRUG: Docetaxel
OTHER: Pharmacological Study

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]